Profile data is unavailable for this security.
About the company
Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.
- Revenue in AUD (TTM)1.39m
- Net income in AUD-3.14m
- Incorporated2018
- Employees--
- LocationEmyria LtdD2 661 Newcastle StreetLEEDERVILLE 6007AustraliaAUS
- Phone+61 86559-2800
- Fax+61 86559-2829
- Websitehttps://www.emeraldclinics.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BTC Health Ltd | 3.28k | -1.04m | 22.52m | 1.00 | -- | 2.04 | -- | 6,865.74 | -0.0033 | -0.0033 | 0.00001 | 0.031 | 0.0003 | -- | -- | -- | -9.70 | -13.71 | -9.92 | -14.66 | -- | -- | -31,820.43 | -3,966.34 | -- | -0.9016 | 0.0066 | -- | -39.12 | -43.28 | 277.27 | -- | -- | -- |
| Holista Colltech Limited | 5.83m | 584.85k | 25.75m | 3.00 | 31.82 | -- | 39.82 | 4.42 | 0.0022 | 0.0023 | 0.0195 | -0.0016 | 1.76 | 3.83 | 5.84 | -- | 17.53 | -46.13 | -- | -85.40 | 49.66 | 55.15 | 9.98 | -38.85 | 0.3782 | 3.93 | -- | -- | -5.82 | -5.07 | 97.92 | -- | -37.01 | -- |
| Argenica Therapeutics Ltd | 332.69k | -9.80m | 28.26m | -- | -- | 8.21 | -- | 84.95 | -0.0762 | -0.0762 | 0.0026 | 0.0268 | 0.0323 | -- | 1.79 | -- | -95.10 | -47.11 | -117.81 | -55.90 | -- | -- | -2,945.67 | -2,938.71 | -- | -40,666.84 | 0.00 | -- | 166.93 | 359.61 | -30.86 | -- | -- | -- |
| Algorae Pharmaceuticals Ltd | 141.05k | -802.96k | 28.91m | -- | -- | 12.87 | -- | 204.95 | -0.0005 | -0.0005 | 0.00008 | 0.0013 | 0.0505 | -- | 3.38 | -- | -28.72 | -51.95 | -30.63 | -56.76 | -- | -- | -569.27 | -1,452.78 | -- | -- | 0.00 | -- | 12.66 | -23.93 | 61.68 | -- | -- | -- |
| Neuroscientific Biopharmaceuticals Ltd | 166.08k | -1.85m | 34.92m | -- | -- | 2.08 | -- | 210.26 | -0.0126 | -0.0126 | 0.0011 | 0.0506 | 0.0148 | -- | 2.17 | -- | -16.48 | -37.13 | -16.65 | -40.11 | -- | -- | -1,111.22 | -185.57 | -- | -746.17 | 0.00 | -- | -93.05 | 16.84 | -669.23 | -- | -- | -- |
| Anteotech Ltd | 1.03m | -6.76m | 35.68m | 40.00 | -- | 10.31 | -- | 34.72 | -0.0025 | -0.0025 | 0.0004 | 0.0012 | 0.1299 | -- | 6.90 | -- | -85.41 | -76.84 | -106.22 | -87.65 | -- | -- | -657.69 | -1,253.69 | -- | -- | 0.3835 | -- | 99.60 | 27.97 | 23.89 | -- | -4.02 | -- |
| Emyria Ltd | 1.39m | -3.14m | 42.75m | -- | -- | 6.11 | -- | 30.65 | -0.0069 | -0.0069 | 0.0031 | 0.0087 | 0.2316 | -- | 40.72 | -- | -52.19 | -82.51 | -69.83 | -106.69 | 1.76 | -17.98 | -225.33 | -355.61 | -- | -22.44 | 0.1037 | -- | -36.68 | 6.60 | 72.57 | -- | -41.45 | -- |
| Syntara Ltd | 7.48m | -12.26m | 50.64m | 107.00 | -- | 3.14 | -- | 6.77 | -0.0084 | -0.0054 | 0.0051 | 0.0099 | 0.4701 | -- | 2.53 | -- | -77.03 | -36.39 | -116.54 | -50.26 | -- | -- | -163.86 | -78.37 | -- | -953.38 | 0.0052 | -- | 37.80 | -9.83 | 10.31 | -- | -- | -- |
| Entropy Neurodynamics Ltd | 1.59m | -5.33m | 53.18m | -- | -- | 8.20 | -- | 33.50 | -0.0043 | -0.0043 | 0.0012 | 0.0041 | 0.2249 | -- | 0.763 | -- | -75.55 | -- | -92.06 | -- | -- | -- | -335.91 | -- | -- | -100.79 | 0.00 | -- | -- | -10.25 | -- | -- | -26.73 | -- |
| Proteomics International LaboratoriesLtd | 3.31m | -8.11m | 56.16m | -- | -- | 4.22 | -- | 16.96 | -0.0605 | -0.0605 | 0.0247 | 0.0805 | 0.2582 | -- | 12.02 | -- | -63.57 | -63.62 | -68.88 | -71.91 | -- | -- | -246.18 | -222.10 | -- | -- | 0.021 | -- | 1.34 | 15.81 | -27.27 | -- | -54.88 | -- |
| Clever Culture Systems Ltd | 6.23m | -744.00k | 58.78m | 17.00 | -- | 7.32 | -- | 9.44 | -0.0004 | -0.0004 | 0.0032 | 0.0037 | 0.5403 | 0.5939 | 3.12 | -- | -6.45 | -36.73 | -8.33 | -42.00 | 80.83 | -- | -11.94 | -281.21 | 1.94 | -7.62 | 0.1406 | -- | 397.86 | 30.08 | 145.03 | -- | 24.71 | -- |
| Amplia Therapeutics Ltd | 5.01m | -7.93m | 61.57m | 1.00 | -- | 1.43 | -- | 12.30 | -0.0204 | -0.0204 | 0.0128 | 0.0837 | 0.1705 | -- | 1.28 | -- | -27.01 | -27.37 | -28.31 | -30.38 | -- | -- | -158.46 | -180.53 | -- | -- | 0.0088 | -- | -15.01 | 156.11 | -45.93 | -- | -- | -- |
